Document is current
Any future updates will be listed below
-
Authors
Singh, Ravinder https://orcid.org/0009-0001-6484-1365
Tuominen, Samuli https://orcid.org/0000-0002-1879-0739
Lassenius, Mariann I. https://orcid.org/0000-0003-0511-3939
Auvinen, Merja
Torstensson, Astrid
Wiklund, Tom https://orcid.org/0000-0002-9384-9614
-
Funding
Funding for this research was provided by:
Eli Lilly Sweden
- License Information
-
More Information
Article History
Received: 7 October 2024
Accepted: 13 December 2024
First Online: 14 February 2025
Declarations
:
: The study was funded by Eli Lilly Sweden. Funding source participated in study concept/design, interpretation of results, writing of the manuscript and the decision to submit the paper for publication. Samuli Tuominen and Mariann I. Lassenius are employed by Medaffcon Oy (Espoo, Finland), which received payments from Eli Lilly (Sweden) for conducting the study. Ravinder Singh is employed by Eli Lilly and Company, Oslo, Norway. Merja Auvinen is an employee of Medaffcon who was contracted by Eli Lilly Company (Helsinki, Finland) during the conduct of the study. Astrid Torstensson is employed by Eli Lilly and Company, Solna, Sweden. Tom Wiklund reports personal fees from Eli Lilly Finland for Scientific Committee participation during study conduct, personal fees from Eli Lilly, Seagen, MSD, outside the submitted work, and participation in Advisory Board of Novartis and Gilead outside the submitted work.
: This non-interventional, retrospective register study was conducted in accordance with the Declaration of Helsinki and the Act on Secondary Use of Health and Social Data 552/2019, Finland. The study permission was granted by the Finnish Social and Health Data Permit Authority Findata (permission number THL/6325/14.02.00/2020). Ethical approval and written informed consents were not needed as the present study was based on secondary use of register data, as authorized by Findata in accordance with the Act on Secondary Use of Health and Social Data.
